Deep-pocketed investors have adopted a bullish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 39 extraordinary options activities for Eli Lilly. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 33% bearish. Among these notable options, 9 are puts, totaling $927,681, and 30 are calls, amounting to $1,799,357.
Expected Price Movements
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $550.0 to $910.0 for Eli Lilly over the last 3 months.
Insights into Volume & Open Interest
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Eli Lilly's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Eli Lilly's significant trades, within a strike price range of $550.0 to $910.0, over the past month.
Eli Lilly Call and Put Volume: 30-Day Overview
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | PUT | SWEEP | NEUTRAL | 01/16/26 | $98.5 | $96.85 | $98.5 | $840.00 | $551.7K | 471 | 61 |
| LLY | CALL | SWEEP | BEARISH | 02/21/25 | $66.1 | $64.4 | $64.35 | $770.00 | $321.7K | 291 | 51 |
| LLY | CALL | TRADE | NEUTRAL | 02/21/25 | $18.95 | $18.15 | $18.5 | $850.00 | $283.0K | 1.1K | 157 |
| LLY | CALL | SWEEP | NEUTRAL | 02/07/25 | $23.75 | $22.6 | $23.16 | $825.00 | $185.2K | 318 | 107 |
| LLY | PUT | TRADE | NEUTRAL | 08/15/25 | $116.95 | $113.95 | $115.65 | $900.00 | $69.3K | 108 | 68 |
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
After a thorough review of the options trading surrounding Eli Lilly, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Eli Lilly's Current Market Status
- Currently trading with a volume of 499,967, the LLY's price is down by -0.02%, now at $823.09.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 6 days.
What The Experts Say On Eli Lilly
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $1080.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Eli Lilly, targeting a price of $1190. * Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Eli Lilly with a target price of $970.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Eli Lilly, Benzinga Pro gives you real-time options trades alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
